Table 3.
Categorical change in five‐dimension European quality of life questionnaire utility index score at 36 months
| Liraglutide | Placebo | P * | |||
|---|---|---|---|---|---|
| N (%) | Mean (SD)a | N (%) | Mean (SD)a | ||
| Total | 1256 (100.0) | −0.05 (0.25) | 1204 (100.0) | −0.07 (0.26) | 0.4156 |
| Worsening | 205 (16.3) | −0.28 (0.19) | 195 (16.2) | −0.29 (0.20) | |
| No change | 919 (73.2) | ‐ | 897 (74.5) | ‐ | |
| No problems → still no problems | 262 (20.9) | 0.00 (0.00) | 242 (20.1) | 0.00 (0.00) | |
| Problems → still problems | 657 (52.3) | −0.05 (0.28) | 655 (54.4) | −0.08 (0.28) | |
| Improvement | 132 (10.5) | 0.23 (0.11) | 112 (9.3) | 0.25 (0.17) | |
Abbreviations: EQ‐5D, five‐dimension European Quality of Life questionnaire; SD, standard deviation. Full analysis set. No adjustment for multiplicity has been made to the P value. A utility index score of 1 is classified as “no problems”, whereas scores <1 are classified as “problems”.
*
P value from Kruskal–Wallis test of treatment difference in four‐point shift, ranked in order of severity (worsening; problems to still problems; no problems to still no problems; improvement).
a
Mean (SD) change in EQ‐5D utility index score within the category.